Arvinas (ARVN) vs Puma Biotechnology (PBYI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Puma Biotechnology (PBYI) has outperformed Arvinas (ARVN) over the past year, gaining 97.5% versus a loss of 20.3%. Over five years, PBYI leads with a +70.1% price change compared with -91.0% for ARVN. Puma Biotechnology is the larger company by market cap ($531.2 million vs $492.9 million), about 1.1 times the size.
On valuation, Puma Biotechnology trades at a lower trailing P/E (20.2x vs 29.4x for Arvinas).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARVN | PBYI |
|---|---|---|
| Share price | $7.64 | $10.29 |
| Market cap | $492.94M | $531.17M |
| 1-day change | +1.73% | +3.21% |
| YTD return | -35.58% | +72.94% |
| 1-year return | -20.33% | +97.50% |
| 5-year return | -91.02% | +70.08% |
| P/E ratio (TTM) | 29.38 | 20.18 |
| Forward P/E | — | 29.40 |
| EPS (TTM) | $0.26 | $0.51 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.51 | $10.36 |
| 52-week low | $6.97 | $4.58 |
| Distance from 52-week high | -47.35% | -0.68% |
| Analyst consensus | buy | none |
| Avg. price target upside | +82.33% | — |
| Average volume | 790.35K | 320.08K |
| Shares outstanding | 64.52M | 51.62M |
| Employees | 246 | 179 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PBYI has outperformed ARVN by 117.8 percentage points over the past year.
- Arvinas trades at a higher earnings multiple (29.4x vs 20.2x trailing P/E).
About Arvinas
ARVN stock →Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.
Health Care · Biotechnology: Pharmaceutical Preparations · 246 employees
About Puma Biotechnology
PBYI stock →Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.
Health Care · Biotechnology: Pharmaceutical Preparations · 179 employees
ARVN vs PBYI FAQ
Which is bigger, Arvinas or Puma Biotechnology?
Puma Biotechnology (PBYI) is larger, with a market capitalization of $531.17M compared with $492.94M for Arvinas (ARVN).
Which stock has performed better over the past year, ARVN or PBYI?
PBYI returned +97.50% over the past 12 months, compared with -20.33% for ARVN (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ARVN or PBYI?
PBYI has the lower trailing P/E at 20.2, versus 29.4 for ARVN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Arvinas and Puma Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.